| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$115,700 ) |
| | 2026 | 2023 | SARC | 24 FRANK LLOYD WRIGHT DR | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 000 | 5 | NIH | 1/6/2026 | $0 |
| | 2026 | 2023 | SARC | 24 FRANK LLOYD WRIGHT DR | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 001 | 5 | NIH | 1/21/2026 | -$115,700 |
|
| Issue Date FY: 2023 ( Subtotal = $111,060 ) |
| | 2023 | 2023 | SARC | 24 FRANK LLOYD WRIGHT DR | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 001 | 5 | NIH | 7/31/2023 | $111,060 |
| | 2023 | 2022 | SARC | 24 FRANK LLOYD WRIGHT DR | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 000 | 4 | NIH | 4/18/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $571,948 ) |
| | 2022 | 2022 | SARC | 24 FRANK LLOYD WRIGHT DR | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 000 | 4 | NIH | 8/17/2022 | $571,948 |
|
| Issue Date FY: 2021 ( Subtotal = $357,335 ) |
| | 2021 | 2021 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 000 | 3 | NIH | 6/30/2021 | $357,335 |
|
| Issue Date FY: 2020 ( Subtotal = $494,871 ) |
| | 2020 | 2020 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 000 | 2 | NIH | 7/20/2020 | $336,096 |
| | 2020 | 2020 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 001 | 2 | NIH | 8/28/2020 | $158,775 |
|
| Issue Date FY: 2019 ( Subtotal = $473,616 ) |
| | 2019 | 2019 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 001 | 1 | NIH | 6/25/2019 | $55,366 |
| | 2019 | 2019 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U01CA236220 | A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcoma | 000 | 1 | NIH | 6/13/2019 | $418,251 |
| | 2019 | 2016 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 5 | NIH | 2/14/2019 | -$1 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2016 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 001 | 5 | NIH | 1/24/2017 | $17,129 |
| | 2017 | 2015 | SARC | 24 FRANK LLOYD WRIGHT DR STE A3100 | ANN ARBOR | MI | 48105-9484 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 4 | NIH | 1/24/2017 | -$17,129 |
|
| Issue Date FY: 2016 ( Subtotal = $2,209,691 ) |
| | 2016 | 2016 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 001 | 5 | NIH | 8/29/2016 | $47,692 |
| | 2016 | 2016 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 5 | NIH | 8/23/2016 | $2,161,999 |
|
| Issue Date FY: 2015 ( Subtotal = $2,185,000 ) |
| | 2015 | 2015 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 4 | NIH | 8/26/2015 | $2,185,000 |
|
| Issue Date FY: 2014 ( Subtotal = $2,162,001 ) |
| | 2014 | 2014 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 3 | NIH | 9/15/2014 | $2,162,001 |
|
| Issue Date FY: 2013 ( Subtotal = $2,150,500 ) |
| | 2013 | 2013 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 002 | 2 | NIH | 8/22/2013 | $2,150,500 |
| | 2013 | 2012 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 1 | NIH | 10/18/2012 | $0 |
| | 2013 | 2012 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 001 | 1 | NIH | 2/8/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $2,300,000 ) |
| | 2012 | 2012 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 001 | 1 | NIH | 10/18/2012 | $0 |
| | 2012 | 2012 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | U54CA168512 | SARC Sarcoma SPORE | 000 | 1 | NIH | 9/26/2012 | $2,300,000 |
|
| Issue Date FY: 2004 ( Subtotal = $8,500 ) |
| | 2004 | 2004 | SARC INC | 110 MILLER | ANN ARBOR | MI | 48104 | WASHTENAW | USA | R13CA113090 | EVALUATING CLINICAL BENEFIT IN SARCOMAS | 000 | 1 | NIH | 9/23/2004 | $8,500 |
|
|
